Rosetta Genomics announces Alzheimer's agreement with global pharma company Rosetta Genomics announces that it has signed an agreement with a global pharmaceutical company, or GPC, in the area of Alzheimer's disease, or AD, diagnostics. Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD. Rosetta will leverage the GPC's expertise in AD as it is considered a pioneer in the development and commercialization of therapeutics for AD.
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.